ACE2 has been reported to inhibit cancer progression in liver hepatocellular carcinoma (LIHC) 17 and pancreatic adenocarcinoma (PAAD) 18, whereas opposite results were observed in kidney renal clear cell carcinoma (KIRC) 19. The gene discussed is ACE2; the disease is cancer.